Regeneron Pharmaceuticals annual net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Regeneron Pharmaceuticals Net Income Growth & History (REGN)
Regeneron Pharmaceuticals's net income was $4.50B for fiscal 2025.
View full Regeneron Pharmaceuticals company overviewRegeneron Pharmaceuticals annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.50B | $92.3M | +2.09% |
| 2024 | 2024-12-31 | $4.41B | $459.0M | +11.61% |
| 2023 | 2023-12-31 | $3.95B | −$384.8M | −8.87% |
| 2022 | 2022-12-31 | $4.34B | −$3.74B | −46.28% |
| 2021 | 2021-12-31 | $8.08B | $4.56B | +129.86% |
| 2020 | 2020-12-31 | $3.51B | $1.40B | +66.05% |
| 2019 | 2019-12-31 | $2.12B | −$328.6M | −13.44% |
| 2018 | 2018-12-31 | $2.44B | $1.25B | +103.95% |
| 2017 | 2017-12-31 | $1.20B | $303.0M | +33.84% |
| 2016 | 2016-12-31 | $895.5M | $259.4M | +40.79% |
| 2015 | 2015-12-31 | $636.1M | $297.9M | +88.11% |
| 2014 | 2014-12-31 | $338.1M | −$75.6M | −18.28% |
| 2013 | 2013-12-31 | $413.7M | −$336.5M | −44.85% |
| 2012 | 2012-12-31 | $750.3M | $972.0M | — |
| 2011 | 2011-12-31 | −$221.8M | −$117.3M | — |
| 2010 | 2010-12-31 | −$104.5M | −$36.6M | — |
| 2009 | 2009-12-31 | −$67.8M | $11.3M | — |
| 2008 | 2008-12-31 | −$79.1M | — | — |
Regeneron Pharmaceuticals quarterly net income
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.30B | −$94.7M | −6.81% |
| Q1 2026 | 2026-03-31 | $727.2M | −$81.5M | −10.08% |
| Q4 2025 | 2025-12-31 | $844.6M | −$73.1M | −7.97% |
| Q3 2025 | 2025-09-30 | $1.46B | $119.4M | +8.91% |
| Q2 2025 | 2025-06-30 | $1.39B | −$40.7M | −2.84% |
| Q1 2025 | 2025-03-31 | $808.7M | $86.7M | +12.01% |
| Q4 2024 | 2024-12-31 | $917.7M | −$241.9M | −20.86% |
| Q3 2024 | 2024-09-30 | $1.34B | $332.8M | +33.02% |
| Q2 2024 | 2024-06-30 | $1.43B | $463.9M | +47.90% |
| Q1 2024 | 2024-03-31 | $722.0M | −$95.8M | −11.71% |
| Q4 2023 | 2023-12-31 | $1.16B | −$37.5M | −3.13% |
| Q3 2023 | 2023-09-30 | $1.01B | −$307.9M | −23.40% |
| Q2 2023 | 2023-06-30 | $968.4M | $116.3M | +13.65% |
| Q1 2023 | 2023-03-31 | $817.8M | −$155.7M | −15.99% |
| Q4 2022 | 2022-12-31 | $1.20B | −$1.03B | −46.29% |
| Q3 2022 | 2022-09-30 | $1.32B | −$316.5M | −19.39% |
| Q2 2022 | 2022-06-30 | $852.1M | −$2.25B | −72.50% |
| Q1 2022 | 2022-03-31 | $973.5M | −$141.7M | −12.71% |
| Q4 2021 | 2021-12-31 | $2.23B | $1.08B | +93.96% |
| Q3 2021 | 2021-09-30 | $1.63B | $790.1M | +93.82% |
| Q2 2021 | 2021-06-30 | $3.10B | $2.20B | +245.36% |
| Q1 2021 | 2021-03-31 | $1.12B | $490.6M | +78.55% |
| Q4 2020 | 2020-12-31 | $1.15B | $357.2M | +45.10% |
| Q3 2020 | 2020-09-30 | $842.1M | $172.5M | +25.76% |
| Q2 2020 | 2020-06-30 | $897.3M | $704.2M | +364.68% |
| Q1 2020 | 2020-03-31 | $624.6M | $163.5M | +35.46% |
| Q4 2019 | 2019-12-31 | $792.0M | −$28.4M | −3.46% |
| Q3 2019 | 2019-09-30 | $669.6M | $74.9M | +12.59% |
| Q2 2019 | 2019-06-30 | $193.1M | −$358.3M | −64.98% |
| Q1 2019 | 2019-03-31 | $461.1M | −$16.9M | −3.54% |
| Q4 2018 | 2018-12-31 | $820.4M | $646.9M | +372.85% |
| Q3 2018 | 2018-09-30 | $594.7M | $206.4M | +53.15% |
| Q2 2018 | 2018-06-30 | $551.4M | $163.7M | +42.22% |
| Q1 2018 | 2018-03-31 | $478.0M | $229.1M | +92.04% |
| Q4 2017 | 2017-12-31 | $173.5M | −$79.6M | −31.45% |
| Q3 2017 | 2017-09-30 | $388.3M | $123.5M | +46.64% |
| Q2 2017 | 2017-06-30 | $387.7M | $191.5M | +97.59% |
| Q1 2017 | 2017-03-31 | $248.9M | $67.5M | +37.22% |
| Q4 2016 | 2016-12-31 | $253.1M | $98.1M | +63.31% |
| Q3 2016 | 2016-09-30 | $264.8M | $54.4M | +25.86% |
| Q2 2016 | 2016-06-30 | $196.2M | $1.6M | +0.81% |
| Q1 2016 | 2016-03-31 | $181.4M | $105.4M | +138.60% |
| Q4 2015 | 2015-12-31 | $155.0M | $64.9M | +72.03% |
| Q3 2015 | 2015-09-30 | $210.4M | $127.0M | +152.35% |
| Q2 2015 | 2015-06-30 | $194.6M | $98.3M | +102.01% |
| Q1 2015 | 2015-03-31 | $76.0M | $7.7M | +11.30% |
| Q4 2014 | 2014-12-31 | $90.1M | −$6.7M | −6.93% |
| Q3 2014 | 2014-09-30 | $83.4M | −$57.9M | −41.00% |
| Q2 2014 | 2014-06-30 | $96.4M | $9.0M | +10.27% |
| Q1 2014 | 2014-03-31 | $68.3M | −$30.6M | −30.92% |
| Q4 2013 | 2013-12-31 | $96.8M | −$373.6M | −79.42% |
| Q3 2013 | 2013-09-30 | $141.3M | −$50.2M | −26.20% |
| Q2 2013 | 2013-06-30 | $87.4M | $10.6M | +13.86% |
| Q1 2013 | 2013-03-31 | $98.9M | $87.2M | +748.63% |
| Q4 2012 | 2012-12-31 | $470.4M | $523.9M | — |
| Q3 2012 | 2012-09-30 | $191.5M | $253.8M | — |
| Q2 2012 | 2012-06-30 | $76.7M | $139.2M | — |
| Q1 2012 | 2012-03-31 | $11.7M | $55.1M | — |
| Q4 2011 | 2011-12-31 | −$53.4M | −$38.8M | — |
| Q3 2011 | 2011-09-30 | −$62.4M | −$28.5M | — |
| Q2 2011 | 2011-06-30 | −$62.5M | −$37.0M | — |
| Q1 2011 | 2011-03-31 | −$43.4M | −$12.9M | — |
| Q4 2010 | 2010-12-31 | −$14.6M | — | — |
| Q3 2010 | 2010-09-30 | −$33.9M | −$32.9M | — |
| Q2 2010 | 2010-06-30 | −$25.5M | −$10.5M | — |
| Q1 2010 | 2010-03-31 | −$30.5M | — | — |
| Q3 2009 | 2009-09-30 | −$1.0M | — | — |
| Q2 2009 | 2009-06-30 | −$14.9M | — | — |
Regeneron Pharmaceuticals net income trends
Over the last five fiscal years, Regeneron Pharmaceuticals's net income increased from $3.51B to $4.50B, a change of $991.7M. The latest reported quarter, Q2 2026, shows $1.30B.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regeneron Pharmaceuticals source filings ↗